The U.S. Food and Drug Administration (FDA) has taken the first step towards allowing the production of seven peptides, previously restricted due to safety concerns, by compounding pharmacies. This decision by the FDA could facilitate the use of peptides in medical treatments and increase access to peptide-based therapies in the healthcare sector. These peptides had previously been limited in production due to safety risks. This new regulatory step by the FDA may allow controlled production of peptides in compounding pharmacies. However, the progress of this process and the final decision will depend on the FDA's evaluations.